Physician profile
Melissa Mora
NPI 1992938203
$11,863.58
in general payments reported to CMS, 2019-2025
51 companies · $1,860 in 2025
The $1,860 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,966 · 2020: $1,301 · 2021: $1,577 · 2022: $1,657 · 2023: $1,585 · 2024: $1,918 · 2025: $1,860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,363.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,775.25 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $1,240.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,217.32 | 2019-2025 | |
| Novo Nordisk INC | $1,118.35 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $958.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $912.43 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $457.21 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $419.17 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $394.76 | 2019-2025 | |
| Amarin Pharma, INC. | $280.93 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $220.61 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $219.87 | 2019-2023 | Belsomra |
| Biohaven Pharmaceutical Holding Company LTD. | $207.45 | 2022 | |
| Currax Pharmaceuticals LLC | $185.11 | 2019-2024 | Contrave, Onzetra Xsail |
| Supernus Pharmaceuticals, INC. | $172.98 | 2019-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Mora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.